Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology.

诺华（Novartis）已达成另一项协议，以巩固其在放射性药物领域的地位，同意为放射性配体治疗（RLT）开发商马里亚纳肿瘤学（MarianaOncology）预付10亿美元。

The deal also includes up to $750 million in future milestone payments – with the total value pretty impressive considering that Mariana’s RLT candidates are all still in preclinical development – but is yet more evidence of Novartis’ determination to become the leading player in the category.

这笔交易还包括未来高达7.5亿美元的里程碑付款——考虑到马里亚纳的RLT候选人仍处于临床前开发阶段，总价值相当可观，但这进一步证明了诺华决心成为该领域的领先者。

The pharma group said buying Mariana would expand its pipeline with several programmes – headed by an RLT for small cell lung cancer (SCLC) called MC-339 – and also bolster its R&D and clinical supply capabilities in radiopharma.

该制药集团表示，收购马里亚纳将通过几个项目扩大其渠道，这些项目由名为MC-339的小细胞肺癌RLT（SCLC）领导，还将增强其在放射制药领域的研发和临床供应能力。

Novartis has been growing its position in the sector mainly by acquisition, starting with its $3.9 billion takeover of Advanced Accelerator Applications in 2017, which gave it Lutathera (lutetium [177Lu] oxodotreotide) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

诺华在该行业的地位一直在增长，主要是通过收购，从2017年以39亿美元收购先进加速器应用开始，这使其获得了用于胃肠胰神经内分泌肿瘤（GEP-NETs）的Lutathera（lutetium[177Lu]oxodotrotide）。

That was followed in 2019 by a $2.1 billion purchase of Endocyte and its prostate cancer RLT Pluvicto (lutetium [lu177] vipivotide tetraxetan), which made sales of almost $1 billion in 2023 and according to Novartis could become a $2 billion-a-year product with extensions to its label.

随后，2019年斥资21亿美元收购了Endocyte及其前列腺癌RLT-Pluvicto（lutetium[lu177]vipivotide tetraxetan），2023年销售额近10亿美元，据诺华称，该产品有望成为一种年销售额20亿美元的产品，并扩展其标签。

Fast forward another two years, and the company added to its RLT pipeline via licensing deals with Artios Pharma and iTheranostics, while just this week it paid $180 million to PeptiDream to partner on the development of peptide-drug conjugate (PDCs) that will be used to target RLTs to tumour sites.

再过两年，该公司通过与Artios Pharma和iTheranostics的许可协议增加了RLT管道，而就在本周，该公司向PeptiDream支付了1.8亿美元，以合作开发肽-药物偶联物（pDC），用于将RLT靶向肿瘤部位。

The latter deal includes milestone payments of up to $2.7 billion..

后一笔交易包括高达27亿美元的里程碑付款。。

Mariana has developed an RLT platform that spans targeting ligands that it says can penetrate more deeply and evenly into tumours and are rapidly cleared from the body to reduce toxicity, as well as alpha and beta particle-emitting payloads.

Mariana开发了一种RLT平台，该平台跨越靶向配体，可以更深入，更均匀地渗透到肿瘤中，并迅速从体内清除以降低毒性，以及释放α和β粒子的有效载荷。

Its lead projects are peptide-based ligands joined to alpha-emitting actinium agents that offer more limited penetrating power, reducing any off-target side effects, and may also be less prone to the development of treatment resistance because they introduce breaks across both strands of DNA.

它的主要项目是基于肽的配体，与发射α的锕试剂结合，提供更有限的穿透力，减少任何脱靶副作用，并且可能不太容易产生治疗耐药性，因为它们会在两条DNA链上引入断裂。

The Watertown, Massachusetts biotech was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and grown in the latter’s RAVen incubator, and is the first acquisition of a company from that hub. It raised $75 million in a Series A in 2021and another $175 million in a second round that closed last September..

马萨诸塞州沃特敦生物技术公司（Watertown，Massachusetts biotech）由Atlas Venture、Access Biotechnology和RA Capital Management于2021年成立，并在后者的RAVen孵化器中成长，是该中心首次收购公司。它在2021年的a轮融资中筹集了7500万美元，在去年9月结束的第二轮融资中又筹集了1.75亿美元。。

Founder and chief executive Simon Read said that Novartis is a leader in the commercialisation of radiopharma agents and “together, we offer a compelling combination of capabilities.”

创始人兼首席执行官西蒙·里德（SimonRead）表示，诺华是放射性药物商业化领域的领导者，“我们共同提供了令人信服的能力组合。”